摘要
新型冠状病毒感染的肺炎疫情暴发,提醒我国加强应对突发公共卫生事件能力的重要性。制定快速有效的医疗产品紧急授权制度是应对突发公共卫生事件重要手段。本文通过梳理美国应对公共卫生突发事件的紧急授权相关政策,为我国制定紧急情况下医疗产品授权制度提供参考。
The outbreak of pneumonia caused by novel coronavirus reminds us of the importance of strengthening China’s capacity in order to respond to public health emergencies.Rapid and effective emergency authorization system of medical products is an important tool to deal with public health emergencies.This paper provides a reference for China to build up the authorization system of medical products under emergency situations by sorting out the emergency authorization policies of the United States in response to public health emergencies.
作者
王雪
左书凝
许淑红
张绮
张林琦
王涛
WANG Xue;ZUO Shu-ning;XU Shu-hong;ZHANG Qi;ZHANG Lin-qi;WANG Tao(Research Center of Drug Regulation Science,School of Medicine,Tsinghua University,Beijing 100084,China;Center of Drug Evaluation,National Medical Products Administration,Beijing 100022,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2021年第7期596-600,共5页
Chinese Journal of New Drugs
关键词
新型冠状病毒
医疗产品
紧急授权
COVID-19
medical products
emergency authorization